# Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis

> **NCT00953199** · NA · COMPLETED · sponsor: **Abraham Mathew MD** · enrollment: 506 (actual)

## Conditions studied

- Pancreatitis

## Interventions

- **DRUG:** Lidocaine Hydrochloride
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT00953199
- **Lead sponsor:** Abraham Mathew MD
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 506 (ACTUAL)
- **Last updated:** 2017-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00953199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00953199, "Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00953199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*